NovaCardia Files for IPO

NovaCardia Inc., a San Diego-based drug company focused on cardiovascular disease, has filed for an $86.25 million IPO. It plans to trade on the Nasdaq under ticker symbol NCAR, with JPMorgan and Credit Suisse serving as co-lead underwriters. The company has raised nearly $70 million in VC funding since its 2001 formation, from firms like Domain Associates (24.9% pre-IPO stake), Forward Ventures (15.6%), InterWest Partners (10.4%), Skyline Venture Partners (15.3%), Versant Ventures (13.6%) and Montreaux Equity Partners (12.5%).